Get the Stockscreener App
18.63
0.38%
0.07
Gh Research Plc stock is traded at $18.63, with a volume of 159.49K.
It is up +0.38% in the last 24 hours and down -32.38% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$18.56
Open:
$18.75
24h Volume:
159.49K
Relative Volume:
0.54
Market Cap:
$1.28B
Revenue:
Net Income/Loss:
$-48.26M
P/E Ratio:
-23.59
EPS:
-0.7899
Net Cash Flow:
$-45.04M
1W Performance:
-8.90%
1M Performance:
-32.38%
6M Performance:
+9.59%
1Y Performance:
+28.48%
1-Day Range:
$18.48
$19.39
1-Week Range:
$18.29
$21.30
52-Week Range:
$12.04
$31.44
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
18.63 | 1.28B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.91 | 82.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
847.02 | 53.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-27-26 | Initiated | Wells Fargo | Overweight |
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
GH Research PLC (1KA.HM) balance sheet - Yahoo Finance UK
GH Research PLC (1KA.HM) balance sheet – Yahoo Finance - Yahoo Finance Singapore
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities - Seeking Alpha
GH Research PLC (GHRS) Stock Price Quote Today & Current Price Chart - Capital.com
GH Research Plans Investor Meetings at Morgan Stanley Global Healthcare Conference - TipRanks
$GHRS Q2 '26 Earnings Results & Recap - Stocktwits
GH Research (GHRS) plans one-on-one talks at 2026 Morgan Stanley healthcare event - Stock Titan
Price-Driven Insight from (GHRS) for Rule-Based Strategy - Stock Traders Daily
GH Research (GHRS) director gets 2,303 options not exercisable until 2028 - Stock Titan
Standard Chartered pays GH¢97.8m dividend to SSNIT - Business & Financial Times
(GHRS) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
(GHRS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
GH Research (GHRS) Slides 2.48% to $27.94 as Shares Approach Key SupportBearish Pattern Stocks - vinanet.vn
GH Research (GHRS) Slides 2.48% to $27.94 as Shares Approach Key SupportWyckoff Accumulation - dars.gov.et
GH (GHRS) Results at a Glance: Reported EPS Tops Expectations on the Day; Market Move: Shares Fall 0.81% in the Latest SessionCash Flow Report - dars.gov.et
GH (GHRS) Results at a Glance: Reported EPS Tops Expectations on the Day; Market Move: Shares Fall 0.81% in the Latest SessionGuidance Upgrade Report - https://www.dars.gov.et/
Net margin % of GH Research Plc – HAM:1KA - TradingView
Net income before discontinued operations of GH Research Plc – HAM:1KA - TradingView
Janus (JHG) Results Check: EPS Misses Its Estimate on the Day; Market Move: The Immediate Price Response Is Limited in the Current UpdateBasic EPS Analysis - dars.gov.et
GH Research Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
How Rising Losses And Milestone Spending At GH Research (GHRS) Have Changed Its Investment Story - simplywall.st
GHRS Q2 2026 Earnings: Narrower Loss of -$0.23 Per Share Beats Estimates by 25.6%Earnings Trend Analysis - vinanet.vn
Zacks Research Upgrades GH Research (NASDAQ:GHRS) to Hold - MarketBeat
RA Capital discloses 7.1% GH Research PLC (GHRS) stake in Schedule 13G/A - Stock Titan
Lynx1 Capital Management (NASDAQ: GHRS) reports 19.3% stake in GH Research - Stock Titan
GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
GH Research PLC Director Duncan Moore Granted 2,202 Share Options - Kalkine Media
GH Research PLC (GHRS) director receives 2,202 fully vested share options - Stock Titan
GH Research PLC (GHRS) director receives 2,202 options at $0.025 strike - Stock Titan
GH Research PLC (GHRS) grants 102,202 share options to director Michael Forer - Stock Titan
GH Research PLC Director Dermot John Hanley Secures 2,202 Share Options - Kalkine Media
GH Research (NASDAQ:GHRS) Sees Strong Trading VolumeShould You Buy? - MarketBeat
FY2026 EPS Estimates for GH Research Boosted by Analyst - MarketBeat
GH Research (GHRS) Retreats 2.4% to $29.53 as Clinical-Stage Biotech ConsolidatesDip Buy Trade - dars.gov.et
Trading the Move, Not the Narrative: (GHRS) Edition - Stock Traders Daily
H.C. Wainwright reiterates GH Research stock rating on FDA progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates GH Research stock rating on FDA progress By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates GH Research stock rating on FDA progress - Investing.com
H.C. Wainwright reiterates GH Research stock rating on FDA progress By Investing.com - Investing.com Canada
H.C. Wainwright reiterates GH Research stock rating on FDA progress By Investing.com - Investing.com UK
H.C. Wainwright reiterates GH Research stock rating on FDA progress - Investing.com
Standard Chartered Bank declares GH¢673m dividend • pledges support for economic growth - Ghanaian Times
Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative? - simplywall.st
GH Research (NASDAQ:GHRS) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
GH Research (NASDAQ:GHRS) Upgraded at Wall Street Zen - MarketBeat
GH Research stock hits all-time high at 31.41 USD By Investing.com - Investing.com India
GH Research stock hits all-time high at 31.41 USD By Investing.com - Investing.com UK
GH Research stock hits all-time high at 31.41 USD By Investing.com - Investing.com South Africa
GH Research stock hits all-time high at 31.41 USD By Investing.com - Investing.com Australia
GH Research stock hits all-time high at 31.41 USD By Investing.com - Investing.com Nigeria
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.20%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):